Zonisamide (ZNS) is a broad spectrum antiepileptic drug (AED) showing efficacy in controlling seizures as add-on in adult and paediatric epilepsy. To date, no studies are available on ZNS in patients with braintumor-related epilepsy (BTRE). Aim of the study was to evaluate efficacy and tolerability of ZNS as add-on treatment in BTRE. We followed 6 patients suffering from BTRE treated with other AEDs and not experiencing adequate seizure control. Three patients underwent chemotherapy while being treated with ZNS. Mean duration of follow up was 8 months. Mean seizure number in the month prior to the introduction of ZNS had been 27.7/month. ZNS mean dose was of 283.3 mg/day. At last follow-up, the mean seizure number was reduced to 8.8/month. Two patients discontinued the drug because of side effects. There were no other reported side effects. Preliminary data on the use of ZNS in add-on in patients with BTRE indicate that this drug may represent a valid alternative as add-on in this particular patient population. However larger samples and more prolonged follow-up are necessary to draw definitive conclusions.
|Translated title of the contribution||Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Apr 2010|
ASJC Scopus subject areas
- Clinical Neurology